AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

Nara Smith shared pictures of her recent eczema flare-ups on Instagram, where the model got candid about her journey with the ...

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Being a social media star may seem like the high life but Nara Smith, fashion model-turned-TikTok creator just pulled back the curtain on all that appears glitz and glam by getting candid about her ...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...

It's still early science -- studies in mice and in human cells -- but researchers are on the trail of an effective n ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Nara Smith, known for her picture-perfect content, has opened up about her health challenges, saying it inspired her to start ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...